CSL sees highest patent filings and grants during August in Q3 2023
CSL saw the highest growth of 126% in patent filings and 174% in grants in July in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 126% and grants by 174%. GlobalData's DataBook provides a comprehensive analysis of CSL's patent filings and grants. Buy the databook here.CSL has been focused on protecting inventions in South Korea(KR) with 13 publications in Q3 2023The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 23% filings and 5% grants. The South Korea(KR), Israel(IL), United States(US), and Australia(AU) patent Office are among the top ten patent offices where CSL is filings its patents. Among the top granted patent authorities, CSL has 23% of its grants in United States(US), 14% in European Patent Office(EPO), and 5% in South Korea(KR).Amgen could be the strongest competitor for CSLAmgen and Johnson & Johnson secured the top positions according to recent patent publication data.Patents related to rare diseases and Covid-19 lead CSL's portfolioCSL has the highest number of patents in rare diseases followed by, Covid-19 and climate change. For rare diseases, nearly 43% of patents were filed and 83% of patents were granted in Q3 2023.Hyperphosphatemia related patents lead CSL portfolio followed by renal insufficiency, and mobiles, hand-helds, pdas, smartphonesCSL has highest number of patents in hyperphosphatemia followed by renal insufficiency, mobiles, hand-helds, pdas, smartphones, caries and stroke. For hyperphosphatemia, nearly 0% of patents were filed and 12% of patents were granted in Q3 2023.For comprehensive analysis of CSL's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for CSL here.
What's Your Reaction?
